Alpha-fetoprotein mediated targeting of polymeric nanoparticles to treat solid tumors.
Background: Serious side effects caused by paclitaxel formulation, containing toxic solubilizer Cremophor® EL, and its nonspecific accumulation greatly limit clinical paclitaxel application. Aim: To design paclitaxel-loaded copolymer of lactic and glycolic acids nanoparticles decorated with alpha-fetoprotein third domain (rAFP3d-NP) to increase paclitaxel safety profile. Methods: rAFP3d-NP was obtained via carbodiimide technique. Results: The particles were characterized with high paclitaxel loading content of 5% and size of 280 nm. rAFP3d-NP revealed biphasic profile with 67% release of paclitaxel during 220 h. Increased area under the curveinf and mean residence time values after rAFP3d-NP administration confirmed prolonged blood circulation compared with paclitaxel. rAFP3d-NP demonstrated significant tumor growth inhibition at 4T1 and SKOV-3 models. Conclusion: rAFP3d-NP is a promising delivery system for paclitaxel and can be applied similarly for delivery of other hydrophobic drugs.
Citations by journals
1
2
|
|
Pharmaceutics
|
Pharmaceutics
2 publications, 33.33%
|
Polymers
|
Polymers
2 publications, 33.33%
|
Colloids and Surfaces B: Biointerfaces
|
Colloids and Surfaces B: Biointerfaces
1 publication, 16.67%
|
Biophysics (Russian Federation)
|
Biophysics (Russian Federation)
1 publication, 16.67%
|
1
2
|
Citations by publishers
1
2
3
4
|
|
Multidisciplinary Digital Publishing Institute (MDPI)
|
Multidisciplinary Digital Publishing Institute (MDPI)
4 publications, 66.67%
|
Elsevier
|
Elsevier
1 publication, 16.67%
|
Pleiades Publishing
|
Pleiades Publishing
1 publication, 16.67%
|
1
2
3
4
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.